|Day Low/High||3.50 / 3.71|
|52 Wk Low/High||1.70 / 3.90|
Levi & Korsinsky announces it has commenced an investigation of BioDelivery Sciences International, Inc.
We are coming my favorite part of earnings season -- when these small-caps report.
We answer questions about BioDelivery Sciences, Dynavax Technologies and Synergy Pharmaceuticals.
There still will be winners and losers, but the new administration's FDA is a net plus for the industry.
There are reasons to believe rallies in BioDelivery Sciences and Flexion Therapeutics should continue.
Flexion Therapeutics and BioDelivery Sciences are well below what they once fetched.
These stocks will be great stories in the second half of 2017, and are significantly undervalued.
We answer recent reader questions about three of the biotech stocks we regularly cover.
This biopharma company's Relistor drug should send revenues sharply higher this year.
This biopharma company's Relistor drug should send revenues sharply higher next year.
There are more dogs on the S&P 500 than on the Dow. Here's one example.
These small-caps are woefully undervalued after getting shellacked in October.
BioDelivery Sciences, Progenics Pharma and Sequential Brands are off-the-radar small-caps poised for a big year in 2017.
BioDelivery Sciences' (BDSI) stock rating was boosted at Janney Capital on Friday.
Investors in BioDelivery Sciences International Inc saw new options begin trading this week, for the August 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BDSI options chain for the new August 19th contracts and identified the following call contract of particular interest.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.